1. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. (27th May 2016) Authors: Bendell, Johanna C.; Zakari, Ahmed; Lang, Evan; Waterhouse, David; Flora, Douglas; Alguire, Kathryn; McCleod, Michael; Peacock, Nancy; Ruehlman, Peter; Lane, Cassie M.; Earwood, Chris; Shih, Kent Journal: Cancer investigation Issue: Volume 34:Number 5(2016) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report. (March 2022) Authors: Lang, Evan; Sande, Brenda; Brodkin, Samantha; van Rhee, Frits Journal: Therapeutic advances in hematology Issue: Volume 13(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Tunable tunnel barriers in a semiconductor via ionization of individual atoms. (28th May 2021) Authors: Mueller, Sara M; Kim, Dongjoon; McMillan, Stephen R; Tjung, Steven J; Repicky, Jacob J; Gant, Stephen; Lang, Evan; Bergmann, Fedor; Werner, Kevin; Chowdhury, Enam; Asthagiri, Aravind; Flatté, Michael E; Gupta, Jay A Journal: Journal of physics Issue: Volume 33:Number 27(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗